HRT for Women: The 2026 Guide to Perimenopause and Menopause

Over the last decade, the conversation around hormone replacement therapy for women has undergone a quiet but enormous shift. After nearly 20 years of over-cautious avoidance based on a single flawed trial, the evidence is back, and it tells a different story. Modern HRT, started in the right window and tailored to the individual, is among the most impactful interventions available for women's long-term health.

This guide covers what happens during perimenopause and menopause, how HRT addresses it, what the evidence actually says about risks, and how women can access modern HRT through telehealth.

What happens during perimenopause and menopause

A woman's hormonal life runs on predictable biology. In the 30s and 40s, the ovaries begin producing progressively less estrogen and progesterone. This transition, called perimenopause, can last anywhere from 4 to 10 years before the final menstrual period. Menopause itself is a single point in time: 12 consecutive months without a menstrual period, typically occurring around age 51 in the U.S. Everything after is called postmenopause.

Hormonally, here's what changes:

• Estrogen. Declines erratically during perimenopause, then settles at very low levels postmenopause. Affects almost every tissue, brain, bones, heart, skin, vaginal tissue, metabolism.
• Progesterone. Drops first and often dramatically during perimenopause, before estrogen. Progesterone is calming and sleep-supportive; its loss is felt long before periods stop.
• Testosterone. Women produce testosterone too, at about 1/10 the level of men. It declines gradually from the 20s onward, with significant implications for libido, energy, and lean mass.

Symptoms of hormonal decline

The classic symptoms of perimenopause and menopause:

• Hot flashes and night sweats, affect up to 80% of women
• Sleep disturbance, often the first symptom, driven largely by falling progesterone
• Mood changes, irritability, anxiety, new-onset depression, brain fog
• Cognitive changes, memory lapses, slower word recall, "fuzzy thinking"
• Sexual symptoms, loss of libido, vaginal dryness, painful sex, urinary urgency
• Weight gain, particularly abdominal/visceral fat
• Muscle loss and joint pain, more than people expect
• Heart palpitations, often dismissed but very common
• Skin and hair changes, thinning, dryness, loss of elasticity
• Bone density loss, silent but consequential

What HRT is

Hormone replacement therapy restores hormones that have declined with age, either to relieve symptoms or to reduce disease risk long-term. Modern HRT uses:

• Bioidentical estradiol, chemically identical to your body's estrogen
• Micronized progesterone, the bioidentical version of progesterone
• Testosterone (when appropriate), low-dose for women with symptoms of androgen deficiency

Older HRT used synthetic analogs (conjugated equine estrogens, medroxyprogesterone) with worse risk profiles. These are rarely used anymore in quality HRT practice.

The Women's Health Initiative, setting the record straight

In 2002, the Women's Health Initiative (WHI) published preliminary findings that seemed to show increased breast cancer and cardiovascular risk with HRT. Media coverage was dramatic. HRT prescriptions plummeted. For 20 years, a generation of women avoided HRT based on that one headline.

What the subsequent reanalyses showed:

• The original study used synthetic hormones (conjugated equine estrogens + medroxyprogesterone), not modern bioidentical versions
• The average age at study entry was 63, well past menopause. Women who start HRT at that age do face higher cardiovascular risk.
• In the subgroup of women who started HRT within 10 years of menopause or under age 60, cardiovascular risk was actually reduced, not increased.
• The absolute increase in breast cancer, when it existed, was small (about 8 additional cases per 10,000 women-years) and appears to be driven largely by the specific synthetic progestin used, not estrogen itself.

Modern medical societies, the Menopause Society, Endocrine Society, and others, have updated their positions. The current evidence strongly supports HRT as safe and beneficial when:

• Started within 10 years of menopause or before age 60
• Using bioidentical hormones at physiological doses
• Individually tailored and monitored

Benefits of modern HRT

Symptomatic relief

• 70-90% reduction in hot flashes and night sweats
• Dramatic improvement in sleep quality (especially with progesterone)
• Improvement in mood, anxiety, and depressive symptoms
• Relief of vaginal dryness, painful sex, and urinary symptoms
• Better cognition and reduced "brain fog"

Long-term health benefits

• Bone density preservation. HRT is the most effective prevention for postmenopausal osteoporosis, reducing fracture risk by 30-50%.
• Cardiovascular benefit (when started early). Reduced heart disease risk when HRT begins within the "window of opportunity."
• Reduced all-cause mortality in women who start HRT before age 60, multiple meta-analyses confirm this.
• Possibly reduced dementia risk (evidence is emerging, especially for Alzheimer's).
• Muscle mass and metabolic health preservation.
• Skin and hair maintenance.

Estrogen, progesterone, and testosterone, who needs what

Estrogen (estradiol)

The main hormone addressed in HRT. Replacing estradiol resolves most menopause symptoms and provides the bulk of the long-term health benefits.

Progesterone

Required for women who still have a uterus (to protect the uterine lining from unopposed estrogen, which can cause endometrial cancer). Also produces its own benefits: better sleep, reduced anxiety, and calming effects. Oral micronized progesterone is usually dosed at bedtime.

Testosterone

Often overlooked. Women with low testosterone may experience low libido, fatigue, loss of muscle, brain fog, or flat mood even when on estrogen and progesterone. Low-dose testosterone (1/10 the typical male dose) can be transformative for the right candidates.

Delivery forms

Risks and contraindications

HRT isn't for everyone. Absolute contraindications:

• Active breast cancer or history of hormone-sensitive breast cancer
• Active blood clotting disorders or recent DVT/PE
• Active liver disease
• Unexplained vaginal bleeding (until evaluated)
• Recent stroke or heart attack

For women without contraindications, the real risks are small and quantifiable: a modest possible increase in breast cancer risk with long-term use of combined estrogen+progestogen therapy, a slightly elevated clotting risk with oral (not transdermal) estrogen, and minor side effects like breast tenderness, spotting, or bloating early in treatment. These need to be weighed against the well-documented benefits, which, for most women, are substantially larger than the risks.

The "window of opportunity"

The timing of HRT initiation matters enormously. Starting HRT within 10 years of menopause or before age 60, the "window of opportunity", maximizes benefits and minimizes risks. Starting much later can have a different risk profile (higher cardiovascular risk in particular). This is why women who are peri- or early postmenopausal shouldn't wait until they're "bad enough" to try HRT, the best outcomes come from earlier, not later, treatment.

How to get started with HRT

The typical pathway:

1. Comprehensive hormone panel, estradiol, FSH, LH, total and free testosterone, SHBG, DHEA-S, thyroid panel, metabolic markers.
2. Symptom assessment, structured questionnaires (Menopause Rating Scale, etc.) to quantify severity.
3. Provider consultation, review labs + symptoms + health history, discuss contraindications, recommend protocol.
4. Initial protocol, typically transdermal estradiol + oral progesterone if uterus intact, with testosterone added if indicated.
5. Follow-up at 6-8 weeks, assess response, adjust dose.
6. Annual monitoring, labs, symptoms, mammogram per standard care.

The bottom line

Modern HRT, started in the right window, using bioidentical hormones at physiological doses, individually monitored, is one of the most impactful medical interventions available to women over 40. It addresses symptoms that substantially reduce quality of life, and provides long-term protection against osteoporosis, cardiovascular disease, and possibly dementia.

If you're in your 40s or early 50s and experiencing perimenopausal symptoms, or you're a few years postmenopausal and wondering if you missed the window, get evaluated. The conversation is very different in 2026 than it was in 2005.